Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 11—November 2004

Evaluating Human Papillomavirus Vaccination Programs

Al V. Taira*, Christopher P. Neukermans†, and Gillian D. Sanders†‡Comments to Author 
Author affiliations: *Stanford School of Medicine, Stanford, California, USA; †Stanford University, Stanford, California, USA; ‡Duke University, Durham, North Carolina, USA

Main Article

Table 3

Reduction in lifetime risk of cervical cancer

Cohort % reduction in lifetime
risk of cervical cancer
Full potential of program in 12-year-old girls 64
First cohort of 12-year-old girls vaccinateda 46
24-year-old women who receive catch-up vaccinationb 35
30-year-old women who receive catch-up vaccinationb 17

aThis group experiences a lower reduction in cancer cases because many of their sex partners will be drawn from a population pool that has not been vaccinated.
b24- or 30-year-old women who opt for catch-up vaccination in the first year that the vaccine becomes available.

Main Article

Page created: April 17, 2012
Page updated: April 17, 2012
Page reviewed: April 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.